Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Greinix, HT; Loidolt, H; Rabitsch, W; Schulenburg, A; Keil, F; Mitterbauer, M; Laczika, K; Lechner, K; Dieckmann, K; Fischer, G; Jäger, U; Rosenmayr, A; Knöbl, P; Schwarzinger, I; Höcker, P; Mannhalter, C; Hinterberger, W; Haas, OA; Fonatsch, C; Kalhs, P.
Excellent disease eradication by myeloablative therapy and stem-cell transplantation in patients with acute myelogenous leukemia.
Ann Hematol. 2000; 79(4):206-213
Doi: 10.1007/s002770050580
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Between February 1982 and 1999, 118 consecutive patients (65 male, 53 female) with acute myelogenous leukemia (AML), with a median age of 35 years (range 17-56 years), received stem-cell grafts from a human leukocyte antigen-identical sibling (n = 71), one-antigen-mismatched family member (n=2), matched unrelated donor (n=15), one-antigen-mismatched unrelated donor (n = 4) or an autologous (n = 26) graft. At the time of transplant, 56 patients were in the first complete remission (CR), 27 in the second CR, 6 in untreated relapse, 17 in primary refractory, and 12 in refractory relapse. The French-American-British classification (FAB) subtypes were as follows: M1 (n=25), M2 (n=28), M3 (n=11), M4 (n =32), M5 (n=16), M6 (n = 6). For conditioning, most patients underwent total body irradiation-containing regimens. As of 28 February, 1999, probability of leukemia-free survival (LFS) is 58% for patients after related and 45% after unrelated stem-cell transplantation (SCT). The probability of LFS is 70% for patients given allogeneic transplants in the first CR compared with 33% for those beyond the first CR at SCT. In autologous stem-cell graft recipients, the probability of LFS is 37%. Transplant-related mortality was 28% after related, 20% after unrelated, and 4% after autologous SCT. Probability of relapse for patients given related-donor stem-cell grafts in the first CR and beyond the first CR is 30% and 67%, 55% after unrelated and 63% after autologous stem-cell grafting. Thus, myeloablative therapy followed by allogeneic stem-cell infusion has a high curative potential for patients with AML in remission and offers substantial benefits to patients in advanced disease.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Chromosomes, Human, Pair 15 -
- Chromosomes, Human, Pair 17 -
- Female -
- Gene Rearrangement -
- Hematopoietic Stem Cell Transplantation -
- Humans -
- Leukemia, Myeloid, Acute - therapy
- Long-Term Care -
- Male -
- Middle Aged -
- Myeloablative Agonists - therapeutic use
- Neoplasm, Residual - physiopathology
- Polymerase Chain Reaction -
- Retrospective Studies -
- Reverse Transcriptase Polymerase Chain Reaction -
- Translocation, Genetic -
- Transplantation, Autologous - mortality
- Transplantation, Homologous - mortality
- Find related publications in this database (Keywords)
- acute myelogenous leukemia
- stem-cell transplantation